<code id='C549E1EFA2'></code><style id='C549E1EFA2'></style>
    • <acronym id='C549E1EFA2'></acronym>
      <center id='C549E1EFA2'><center id='C549E1EFA2'><tfoot id='C549E1EFA2'></tfoot></center><abbr id='C549E1EFA2'><dir id='C549E1EFA2'><tfoot id='C549E1EFA2'></tfoot><noframes id='C549E1EFA2'>

    • <optgroup id='C549E1EFA2'><strike id='C549E1EFA2'><sup id='C549E1EFA2'></sup></strike><code id='C549E1EFA2'></code></optgroup>
        1. <b id='C549E1EFA2'><label id='C549E1EFA2'><select id='C549E1EFA2'><dt id='C549E1EFA2'><span id='C549E1EFA2'></span></dt></select></label></b><u id='C549E1EFA2'></u>
          <i id='C549E1EFA2'><strike id='C549E1EFA2'><tt id='C549E1EFA2'><pre id='C549E1EFA2'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:7449
          Christine Kao/STAT

          After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra Collins did what many freshly minted Ph.D.s. do — she went looking for a job at a biotech company. But what was supposed to be a straightforward search has turned into an odyssey.

          Collins has applied for more than 53 positions (and counting). Like a good scientist, she’s gathering data along the way and uses a spreadsheet to track each company’s size and therapeutic focus, as well as whether she was referred for the position and how far she made it through the application process. So far, those efforts have been unsuccessful.

          advertisement

          “I try my best not to take it personally. These are companies that are trying to find an employee who’s going to help them achieve their business goals,” Collins said. “But it is pretty discouraging just repeatedly getting turned down, especially at later stages of the interview process.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more
          GSK to buy asthma
          GSK to buy asthma

          AdobeLONDON—GSKsaidTuesdayitwouldpurchasetheasthma-focuseddrugdeveloperAiolosBiofor$1billionupfront,

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

          PeterMarks,theFDA'stopregulatorofgenetherapies(right),speakswithSTAT'sAdamFeuersteininSanFrancisco.S